Skip to main content Back to Top
Advertisement

9/6/2019

Carbidopa and Levodopa Extended-Release Tablets

Products Affected - Description

    • Sinemet CR extended release tablet, Merck, 25 mg/100 mg, bottle, 100 count, NDC 00006-3919-68 - discontinued
    • Sinemet CR extended release tablet, Merck, 50 mg/200 mg, bottle, 100 count, NDC 00006-3918-68 - discontinued
    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 100 count, NDC 16729-0079-01
    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 1000 count, NDC 16729-0079-17
    • Carbidopa and Levodopa extended release tablet, Mylan Institutional, 25 mg/100 mg, unit-dose blister pack, 100 count, NDC 51079-0923-20
    • Carbidopa and Levodopa extended release tablet, Mylan Institutional, 50 mg/200 mg, unit-dose blister pack, 100 count, NDC 51079-0978-20

Reason for the Shortage

    • Accord has discontinued carbidopa and levodopa 25 mg/100 mg extended-release tablets. The 50 mg/200 mg tablets are on shortage due to problems obtaining active ingredient.
    • Sun Pharma had carbidopa and levodopa extended-release tablets on shortage due to increased demand.
    • Merck will be disontinuing Sinemet CR 50 mg/200 mg tables around November 2019. The 25 mg/100 mL tablets will be discontinued around February 2020.
    • Mylan did not provide a reason for the shortage.

Available Products

    • Carbidopa and Levodopa extended release tablet, Mylan, 25 mg/100 mg, bottle, 100 count, NDC 00378-0088-01
    • Carbidopa and Levodopa extended release tablet, Mylan, 50 mg/200 mg, bottle, 100 count, NDC 00378-0094-01
    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 25 mg/100 mg, 100 count, NDC 62756-0461-88
    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 50 mg/200 mg, 100 count, NDC 62756-0457-88

Estimated Resupply Dates

    • Accord has carbidopa and levodopa 50 mg/200 mg extended-release tablets on allocation.
    • Mylan has carbidopa and levodopa 50 mg/200 mg extended-release tablets in 100 count unit-dose packs on back order and the company estimates a release date of late-September to early-October 2019.

Updated

Updated September 6, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 28, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins